SEARCH

SEARCH BY CITATION

References

  • Abeliovich A., Schmitz Y., Fariñas I. et al. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25(1), 239252.
  • Anwar S., Peters O., Millership S. et al. (2011) Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family. J. Neurosci. 31, 72647274.
  • Arduíno D. M., Esteves A. R. and Cardoso S. M. (2011) Mitochondrial fusion/fission, transport and autophagy in Parkinson's disease: when mitochondria get nasty. Parkinsons Dis. 2011, 767230.
  • Arnold W. P., Mittal C. K., Katsuki S. and Murad F. (1977) Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations. Proc. Natl Acad. Sci. USA 74, 32033207.
  • Arriagada C., Paris I., Sanchez de las Matas M. J. et al. (2004) On the neurotoxicity mechanism of leukoaminochrome o-semiquinone radical derived from dopamine oxidation: mitochondria damage, necrosis, and hydroxyl radical formation. Neurobiol. Dis. 16, 468477.
  • Athanassiadou A., Voutsinas G., Psiouri L., Leroy E., Polymeropoulos M. H., Ilias A., Maniatis G. M. and Papapetropoulos T. (1999) Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein. Am. J. Hum. Genet. 65, 555558.
  • Bae E. J., Lee H. J., Rockenstein E., Ho D. H., Park E. B., Yang N. Y., Desplats P., Masliah E. and Lee S. J. (2012) Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission. J. Neurosci. 32, 1345413469.
  • Bae E. J., Ho D. H., Park E., Jung J. W., Cho K., Hong J. H., Lee H. J., Kim K. P. and Lee S. J. (2013) Lipid peroxidation product 4-Hydroxy-2-Nonenal promotes seeding-capable oligomer formation and cell-to-cell transfer of α-Synuclein. Antioxid. Redox Signal. 18, 770783.
  • Barzilai A., Daily D., Zilkha-Falb R., Ziv I., Offen D., Melamed E. and Shirvan A. (2003) The molecular mechanisms of dopamine toxicity. Adv. Neurol. 91, 7382.
  • Beckman J. S. and Crow J. P. (1993) Pathological implications of nitric oxide, superoxide and peroxynitrite formation. Biochem. Soc. Trans. 21, 330334.
  • Benner E. J., Banerjee R., Reynolds A. D. et al. (2008) Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS ONE 3, e1376.
  • Beyer K. (2007) Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane. Cell Biochem. Biophys. 47, 285299.
  • Bisaglia M., Tosatto L., Munari F., Tessari I., de Laureto P. P., Mammi S. and Bubacco L. (2010) Dopamine quinones interact with alpha-synuclein to form unstructured adducts. Biochem. Biophys. Res. Commun. 394, 424428.
  • Bonini M. G., Radi R., Ferrer-Sueta G., Ferreira A. M. and Augusto O. (1999) Direct EPR detection of the carbonate radical anion produced from peroxynitrite and carbon dioxide. J. Biol. Chem. 274, 1080210806.
  • Borbat P., Ramlall T. F., Freed J. H. and Eliezer D. (2006) Inter-helix distances in lysophospholipid micelle-bound alpha-synuclein from pulsed ESR measurements. J. Am. Chem. Soc. 128, 1000410005.
  • Borghi R., Marchese R., Negro A., Marinelli L., Forloni G., Zaccheo D., Abbruzzese G. and Tabaton M. (2000) Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci. Lett. 287, 6567.
  • Braak H. and Braak E. (2000) Pathoanatomy of Parkinson's disease. J. Neurol. 247 (Suppl 2), II3II10.
  • Braak H., Sandmann-Keil D., Gai W. and Braak E. (1999) Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry. Neurosci. Lett. 265, 6769.
  • Braak H., Del Tredici K., Rüb U., de Vos R. A., Jansen Steur E. N. and Braak E. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197211.
  • Braak H., de Vos R. A., Bohl J. and Del Tredici K. (2006) Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci. Lett. 396, 6772.
  • Braithwaite S. P., Stock J. B. and Mouradian M. M. (2012) α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease. Rev. Neurosci. 23, 191198.
  • Bredt D. S. and Snyder S. H. (1990) Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc. Natl Acad. Sci. USA 87, 682685.
  • Bredt D. S., Hwang P. M. and Snyder S. H. (1990) Localization of nitric oxide synthase indicating a neural role for nitric oxide. Nature 347, 768770.
  • Breydo L., Wu J. W. and Uversky V. N. (2012) α-synuclein misfolding and Parkinson's disease. Biochim. Biophys. Acta 1822, 261285.
  • Buchman V. L. and Ninkina N. (2008) Modulation of alpha-synuclein expression in transgenic animals for modelling synucleinopathies–is the juice worth the squeeze? Neurotox. Res. 14, 329341.
  • Butterfield S., Hejjaoui M., Fauvet B., Awad L. and Lashuel H. A. (2012) Chemical strategies for controlling protein folding and elucidating the molecular mechanisms of amyloid formation and toxicity. J. Mol. Biol. 421, 204236.
  • Cappai R., Leck S. L., Tew D. J. et al. (2005) Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J. 19, 13771379.
  • Chartier-Harlin M. C., Kachergus J., Roumier C. et al. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 11671169.
  • Chéret C., Gervais A., Lelli A., Colin C., Amar L., Ravassard P., Mallet J., Cumano A., Krause K. H. and Mallat M. (2008) Neurotoxic activation of microglia is promoted by a nox1-dependent NADPH oxidase. J. Neurosci. 28, 1203912051.
  • Chu Y. and Kordower J. H. (2007) Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol. Dis. 25, 134149.
  • Cole N. B., Murphy D. D., Lebowitz J., Di Noto L., Levine R. L. and Nussbaum R. L. (2005) Metal-catalyzed oxidation of alpha-synuclein: helping to define the relationship between oligomers, protofibrils, and filaments. J. Biol. Chem. 280, 96789690.
  • Conway K. A., Lee S. J., Rochet J. C., Ding T. T., Williamson R. E. and Lansbury P. T. Jr. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl Acad. Sci. USA 97, 571576.
  • Conway K. A., Rochet J. C., Bieganski R. M. and Lansbury P. T. Jr. (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294, 13461349.
  • Cuervo A. M., Stefanis L., Fredenburg R., Lansbury P. T. and Sulzer D. (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305, 12921295.
  • Cui L., Jeong H., Borovecki F., Parkhurst C. N., Tanese N. and Krainc D. (2006) Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127, 5969.
  • Daiber A., Schildknecht S., Müller J., Kamuf J., Bachschmid M. M. and Ullrich V. (2009) Chemical model systems for cellular nitros(yl)ation reactions. Free Radic. Biol. Med. 47, 458467.
  • Danielson S. R., Held J. M., Schilling B., Oo M., Gibson B. W. and Andersen J. K. (2009) Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson's disease. Anal. Chem. 81(18), 78237828.
  • Danzer K. M., Krebs S. K., Wolff M., Birk G. and Hengerer B. (2009) Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology. J. Neurochem. 111, 192203.
  • Davidson W. S., Jonas A., Clayton D. F. and George J. M. (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 94439449.
  • Desplats P., Lee H. J., Bae E. J., Patrick C., Rockenstein E., Crews L., Spencer B., Masliah E. and Lee S. J. (2009) Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl Acad. Sci. USA 106, 1301013015.
  • Devi L., Raghavendran V., Prabhu B. M., Avadhani N. G. and Anandatheerthavarada H. K. (2008) Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 283, 90899100.
  • Dexter D. T., Wells F. R., Lees A. J., Agid F., Agid Y., Jenner P. and Marsden C. D. (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52, 18301836.
  • Di Giovanni S., Eleuteri S., Paleologou K. E., Yin G., Zweckstetter M., Carrupt P. A. and Lashuel H. A. (2010) Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity. J. Biol. Chem. 285, 1494114954.
  • Di Monte D. A. (2003) The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol. 2, 531538.
  • Ding T. T., Lee S. J., Rochet J. C. and Lansbury P. T. Jr. (2002) Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 41, 1020910217.
  • Duda J. E., Giasson B. I., Chen Q., Gur T. L., Hurtig H. I., Stern M. B., Gollomp S. M., Ischiropoulos H., Lee V. M. and Trojanowski J. Q. (2000) Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am. J. Pathol. 157, 14391445.
  • Ebrahimi-Fakhari D., Cantuti-Castelvetri I., Fan Z., Rockenstein E., Masliah E., Hyman B. T., McLean P. J. and Unni V. K. (2011) Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein. J. Neurosci. 31, 1450814520.
  • Ebrahimi-Fakhari D., McLean P. J. and Unni V. K. (2012) Alpha-synuclein's degradation in vivo: opening a new (cranial) window on the roles of degradation pathways in Parkinson disease. Autophagy 8, 281283.
  • El-Agnaf O. M., Salem S. A., Paleologou K. E. et al. (2003) Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 17, 19451947.
  • El-Agnaf O. M., Salem S. A., Paleologou K. E., Curran M. D., Gibson M. J., Court J. A., Schlossmacher M. G. and Allsop D. (2006) Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 20, 419425.
  • Eliezer D., Kutluay E., Bussell R. Jr. and Browne G. (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. J. Mol. Biol. 307, 10611073.
  • Ellis C. E., Murphy E. J., Mitchell D. C., Golovko M. Y., Scaglia F., Barceló-Coblijn G. C. and Nussbaum R. L. (2005) Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein. Mol. Cell. Biol. 25, 1019010201.
  • Engelender S. (2008) Ubiquitination of alpha-synuclein and autophagy in Parkinson's disease. Autophagy 4, 372374.
  • Exner N., Treske B., Paquet D. et al. (2007) Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J. Neurosci. 27, 1241312418.
  • Exner N., Lutz A. K., Haass C. and Winklhofer K. F. (2012) Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J. 31, 30383062.
  • Fahn S. and Cohen G. (1992) The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 32, 804812.
  • Fauvet B., Fares M. B., Samuel F., Dikiy I., Tandon A., Eliezer D. and Lashuel H. A. (2012a) Characterization of semisynthetic and naturally Nα-acetylated α-synuclein in vitro and in intact cells: implications for aggregation and cellular properties of α-synuclein. J. Biol. Chem. 287, 2824328262.
  • Fauvet B., Mbefo M. K., Fares M. B. et al. (2012b) α-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J. Biol. Chem. 287, 1534515364.
  • Fellner L., Irschick R., Schanda K., Reindl M., Klimaschewski L., Poewe W., Wenning G. K. and Stefanova N. (2013) Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia. Glia 61, 349360.
  • Fenton H. J. H. (1894). Oxidation of tartaric acid in presence of iron. J. Chem. Soc., Trans. 65, 899911.
  • Fernandez E., Garcia-Moreno J. M., Martin de Pablos A. and Chacon J. (2013) May the evaluation of nitrosative stress through selective increase of 3-nitrotyrosine proteins other than nitroalbumin and dominant tyrosine-125/136 nitrosylation of serum α-synuclein serve for diagnosis of sporadic Parkinson's disease? Antioxid. Redox Signal. doi:10.1089/ars.2013.5250.
  • Fink A. L. (2006) The aggregation and fibrillation of alpha-synuclein. Acc. Chem. Res. 39, 628634.
  • Fornstedt B., Pileblad E. and Carlsson A. (1990) In vivo autoxidation of dopamine in guinea pig striatum increases with age. J. Neurochem. 55, 655659.
  • Fortin D. L., Troyer M. D., Nakamura K., Kubo S., Anthony M. D. and Edwards R. H. (2004) Lipid rafts mediate the synaptic localization of alpha-synuclein. J. Neurosci. 24, 67156723.
  • Frein D., Schildknecht S., Bachschmid M. and Ullrich V. (2005) Redox regulation: a new challenge for pharmacology. Biochem. Pharmacol. 70, 811823.
  • Galea E., Feinstein D. L. and Reis D. J. (1992) Induction of calcium-independent nitric oxide synthase activity in primary rat glial cultures. Proc. Natl Acad. Sci. USA 89, 1094510949.
  • Gao H. M., Kotzbauer P. T., Uryu K., Leight S., Trojanowski J. Q. and Lee V. M. (2008) Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J. Neurosci. 28, 76877698.
  • Garcia-Reitböck P., Anichtchik O., Bellucci A. et al. (2010) SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain 133(Pt 7), 20322044.
  • George J. M. (2002) The synucleins. Genome Biol. 3, 3(1):REVIEWS3002.
  • George J. M., Jin H., Woods W. S. and Clayton D. F. (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15, 361372.
  • Giasson B. I., Duda J. E., Murray I. V., Chen Q., Souza J. M., Hurtig H. I., Ischiropoulos H., Trojanowski J. Q. and Lee V. M. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290, 985989.
  • Giulian D., Li J., Leara B. and Keenen C. (1994) Phagocytic microglia release cytokines and cytotoxins that regulate the survival of astrocytes and neurons in culture. Neurochem. Int. 25, 227233.
  • Goedert M., Spillantini M. G., Del Tredici K. and Braak H. (2012) 100 years of Lewy pathology. Nat. Rev. Neurol. 9, 1324.
  • Goldstein S. and Czapski G. (1995) The reaction of NO. with O2.- and HO2.: a pulse radiolysis study. Free Radic. Biol. Med. 19, 505510.
  • Goldstein S., Czapski G., Lind J. and Merényi G. (2001) Carbonate radical ion is the only observable intermediate in the reaction of peroxynitrite with CO(2). Chem. Res. Toxicol. 14, 12731276.
  • Graham D. G. (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14, 633643.
  • Haber F. and Weiss J. (1932) Über die Katalyse des Hydroperoxydes. Naturwissenschaften 20, 948950.
  • Hansen C. and Li J. Y. (2012) Beyond α-synuclein transfer: pathology propagation in Parkinson's disease. Trends Mol. Med. 18, 248255.
  • Hejjaoui M., Haj-Yahya M., Kumar K. S., Brik A. and Lashuel H. A. (2011) Towards elucidation of the role of ubiquitination in the pathogenesis of Parkinson's disease with semisynthetic ubiquitinated α-synuclein. Angew. Chem. Int. Ed. 50, 405409.
  • Hejjaoui M., Butterfield S., Fauvet B. et al. (2012) Elucidating the role of C-terminal post-translational modifications using protein semisynthesis strategies: α-synuclein phosphorylation at tyrosine 125. J. Am. Chem. Soc. 134, 51965210.
  • Herrera F. E., Chesi A., Paleologou K. E., Schmid A., Munoz A., Vendruscolo M., Gustincich S., Lashuel H. A. and Carloni P. (2008) Inhibition of alpha-synuclein fibrillization by dopamine is mediated by interactions with five C-terminal residues and with E83 in the NAC region. PLoS ONE 3, e3394.
  • Hewett J. A. and Hewett S. J. (2012) Induction of nitric oxide synthase-2 expression and measurement of nitric oxide production in enriched primary cortical astrocyte cultures. Methods Mol. Biol. 814, 251263.
  • Hirsch E., Graybiel A. M. and Agid Y. A. (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334, 345348.
  • Hodara R., Norris E. H., Giasson B. I., Mishizen-Eberz A. J., Lynch D. R., Lee V. M. and Ischiropoulos H. (2004) Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J. Biol. Chem. 279, 4774647753.
  • Hokenson M. J., Uversky V. N., Goers J., Yamin G., Munishkina L. A. and Fink A. L. (2004) Role of individual methionines in the fibrillation of methionine-oxidized alpha-synuclein. Biochemistry 43, 46214633.
  • Hsu L. J., Sagara Y., Arroyo A., Rockenstein E., Sisk A., Mallory M., Wong J., Takenouchi T., Hashimoto M. and Masliah E. (2000) alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157, 401410.
  • Huie R. E. and Padmaja S. (1993) The reaction of no with superoxide. Free Radic. Res. Commun. 18, 195199.
  • Ibáñez P., Bonnet A. M., Débarges B., Lohmann E., Tison F., Pollak P., Agid Y., Dürr A. and Brice A. (2004) Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364, 11691171.
  • Ischiropoulos H. (2009) Protein tyrosine nitration–an update. Arch. Biochem. Biophys. 484, 117121.
  • Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H. A., Kittel A. and Saitoh T. (1995) The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467475.
  • Jao C.C., Der-Sarkissian A., Chen J. and Langen R. (2004) Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. Proc. Natl Acad. Sci. USA 101, 83318336.
  • Jao C. C., Hegde B. G., Chen J., Haworth I. S. and Langen R. (2008) Structure of membrane-bound alpha-synuclein from site-directed spin labeling and computational refinement. Proc. Natl Acad. Sci. USA 105, 1966619671.
  • Jenner P. (1991) Oxidative stress as a cause of Parkinson's disease. Acta Neurol. Scand. Suppl. 136, 615.
  • Jensen P. H., Nielsen M. S., Jakes R., Dotti C. G. and Goedert M. (1998) Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem. 273, 2629226294.
  • Kamp F. and Beyer K. (2006) Binding of alpha-synuclein affects the lipid packing in bilayers of small vesicles. J. Biol. Chem. 281, 92519259.
  • Kamp F., Exner N., Lutz A. K. et al. (2010) Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J. 29, 35713589.
  • Kang J. H. and Kim K. S. (2003) Enhanced oligomerization of the alpha-synuclein mutant by the Cu, Zn-superoxide dismutase and hydrogen peroxide system. Mol. Cells 15, 8793.
  • Kaylor J., Bodner N., Edridge S., Yamin G., Hong D. P. and Fink A. L. (2005) Characterization of oligomeric intermediates in alpha-synuclein fibrillation: FRET studies of Y125W/Y133F/Y136F alpha-synuclein. J. Mol. Biol. 353, 357372.
  • Kehrer J. P. (2000) The Haber-Weiss reaction and mechanisms of toxicity. Toxicology 149, 4350.
  • Kim C. and Lee S. J. (2008) Controlling the mass action of alpha-synuclein in Parkinson's disease. J. Neurochem. 107, 303316.
  • Kissner R., Nauser T., Bugnon P., Lye P. G. and Koppenol W. H. (1997) Formation and properties of peroxynitrite as studied by laser flash photolysis, high-pressure stopped-flow technique, and pulse radiolysis. Chem. Res. Toxicol. 10, 12851292.
  • Kordower J. H., Chu Y., Hauser R. A., Freeman T. B. and Olanow C. W. (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14, 504506.
  • Krüger R., Kuhn W., Müller T., Woitalla D., Graeber M., Kösel S., Przuntek H., Epplen J. T., Schöls L. and Riess O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106108.
  • Kubo S., Nemani V. M., Chalkley R. J., Anthony M. D., Hattori N., Mizuno Y., Edwards R. H. and Fortin D. L. (2005) A combinatorial code for the interaction of alpha-synuclein with membranes. J. Biol. Chem. 280, 3166431672.
  • Lashuel H. A., Hartley D., Petre B. M., Walz T. and Lansbury P. T. Jr. (2002a) Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418, 291.
  • Lashuel H. A., Petre B. M., Wall J., Simon M., Nowak R. J., Walz T. and Lansbury P. T., Jr (2002b) Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322, 10891102.
  • Lashuel H. A., Overk C. R., Oueslati A. and Masliah E. (2013) The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 3848.
  • Le W., Rowe D., Xie W., Ortiz I., He Y. and Appel S. H. (2001) Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J. Neurosci. 21, 84478455.
  • Lee H. J., Choi C. and Lee S. J. (2002) Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 277, 671678.
  • Lee H. J., Patel S. and Lee S. J. (2005) Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J. Neurosci. 25, 60166024.
  • Lee E. J., Woo M. S., Moon P. G., Baek M. C., Choi I. Y., Kim W. K., Junn E. and Kim H. S. (2010) Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J. Immunol. 185, 615623.
  • Lee H. J., Suk J. E., Lee K. W., Park S. H., Blumbergs P. C., Gai W. P. and Lee S. J. (2011) Transmission of Synucleinopathies in the Enteric Nervous System of A53T Alpha-Synuclein Transgenic Mice. Exp. Neurobiol. 20, 181188.
  • Leong S. L., Pham C. L., Galatis D., Fodero-Tavoletti M. T., Perez K., Hill A. F., Masters C. L., Ali F. E., Barnham K. J. and Cappai R. (2009) Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation. Free Radic. Biol. Med. 46, 13281337.
  • Li W., Lesuisse C., Xu Y., Troncoso J. C., Price D. L. and Lee M. K. (2004a) Stabilization of α-synuclein protein with aging and familial Parkinson's disease-linked A53T mutation. J. Neurosci. 24, 74007409.
  • Li J., Zhu M., Manning-Bog A. B., Di Monte D. A. and Fink A. L. (2004b) Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J. 18, 962964.
  • Li W., West N., Colla E. et al. (2005) Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl Acad. Sci. USA 102, 21622167.
  • Li J. Y., Englund E., Holton J. L. et al. (2008) Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14, 501503.
  • Li J. Y., Englund E., Widner H., Rehncrona S., Björklund A., Lindvall O. and Brundin P. (2010) Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov. Disord. 25, 10911096.
  • Lindersson E., Beedholm R., Højrup P., Moos T., Gai W., Hendil K. B. and Jensen P. H. (2004) Proteasomal inhibition by alpha-synuclein filaments and oligomers. J. Biol. Chem. 279, 1292412934.
  • Liu F., Hindupur J., Nguyen J. L., Ruf K. J., Zhu J., Schieler J. L., Bonham C. C., Wood K. V., Davisson V. J. and Rochet J. C. (2008) Methionine sulfoxide reductase A protects dopaminergic cells from Parkinson's disease-related insults. Free Radic. Biol. Med. 45, 242255.
  • Liu Y., Qiang M., Wei Y. and He R. (2011) A novel molecular mechanism for nitrated α-synuclein-induced cell death. J. Mol. Cell Biol. 3, 239249.
  • Liu G. H., Qu J., Suzuki K. et al. (2012) Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature 491, 603607.
  • Loeb V., Yakunin E., Saada A. and Sharon R. (2010) (2010) The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition. J. Biol. Chem. 285, 73347343.
  • Lotharius J., Barg S., Wiekop P., Lundberg C., Raymon H. K. and Brundin P. (2002) Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J. Biol. Chem. 277, 3888438894.
  • Lotharius J., Falsig J., van Beek J., Payne S., Dringen R., Brundin P. and Leist M. (2005) Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. J. Neurosci. 25, 63296342.
  • Luk K. C., Song C., O'Brien P., Stieber A., Branch J. R., Brunden K. R., Trojanowski J. Q. and Lee V. M. (2009) Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl Acad. Sci. USA 106, 2005120056.
  • Luk K. C., Kehm V., Carroll J., Zhang B., O'Brien P., Trojanowski J. Q. and Lee V. M. (2012a) Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949953.
  • Luk K. C., Kehm V. M., Zhang B., O'Brien P., Trojanowski J. Q. and Lee V. M. (2012b) Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J. Exp. Med. 209, 975986.
  • Lutz A. K., Exner N., Fett M. E. et al. (2009) Loss of parkin or PINK1 function increases Drp1-dependent mitochondrial fragmentation. J. Biol. Chem. 284(34), 2293822951.
  • Lymar S. V. and Hurst J. K. (1995) Rapid reaction between peroxynitrite ion and carbon dioxide: implications for biological activity. J. Am. Chem. Soc. 117, 88678868.
  • Mak S. K., McCormack A. L., Manning-Bog A. B., Cuervo A. M. and Di Monte D. A. (2010) Lysosomal degradation of alpha-synuclein in vivo. J. Biol. Chem. 285, 1362113629.
  • Maltsev A. S., Ying J. and Bax A. (2012) Impact of N-Terminal Acetylation of α-Synuclein on Its Random Coil and Lipid Binding Properties. Biochemistry 51, 50045013.
  • Maltsev A. S., Chen J., Levine R. L. and Bax A. (2013) Site-specific interaction between α-synuclein and membranes probed by NMR-observed methionine oxidation rates. J. Am. Chem. Soc. 135, 29432946.
  • Martinez-Vicente M., Talloczy Z., Kaushik S. et al. (2008) Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J. Clin. Invest. 118, 777788.
  • Masliah E., Rockenstein E., Adame A. et al. (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 46, 857868.
  • Mazzulli J. R., Armakola M., Dumoulin M., Parastatidis I. and Ischiropoulos H. (2007) Cellular oligomerization of alpha-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence. J. Biol. Chem. 282, 3162131630.
  • McCormack A. L., Mak S. K., Shenasa M., Langston W. J., Forno L. S. and Di Monte D. A. (2008) Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys. J. Neuropathol. Exp. Neurol. 67, 793802.
  • McCormack A. L., Mak S. K., Henderson J. M., Bumcrot D., Farrer M. J. and Di Monte D. A. (2010) Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS ONE 5, e12122.
  • McCormack A. L., Mak S. K. and Di Monte D. A. (2012) Increased α-synuclein phosphorylation and nitration in the aging primate substantia nigra. Cell Death Dis. 3, e315.
  • Merényi G., Lind J., Goldstein S. and Czapski G. (1998) Peroxynitrous acid homolyzes into *OH and *NO2 radicals. Chem. Res. Toxicol. 11, 712713.
  • Michell A. W., Tofaris G. K., Gossage H., Tyers P., Spillantini M. G. and Barker R. A. (2007) The effect of truncated human alpha-synuclein (1–120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease. Cell Transplant. 16, 461474.
  • Mishizen-Eberz A. J., Norris E. H., Giasson B. I., Hodara R., Ischiropoulos H., Lee V. M., Trojanowski J. Q. and Lynch D. R. (2005) Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. Biochemistry 44, 78187829.
  • Mizuno N., Varkey J., Kegulian N. C., Hegde B. G., Cheng N., Langen R. and Steven A. C. (2012) Remodeling of lipid vesicles into cylindrical micelles by α-synuclein in an extended α-helical conformation. J. Biol. Chem. 287, 2930129311.
  • Moskovitz J. (2005) Methionine sulfoxide reductases: ubiquitous enzymes involved in antioxidant defense, protein regulation, and prevention of aging-associated diseases. Biochim. Biophys. Acta 1703, 213219.
  • Murphy D. D., Rueter S. M., Trojanowski J. Q. and Lee V. M. (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20, 32143220.
  • Nakamura K., Nemani V. M., Azarbal F. et al. (2011) Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J. Biol. Chem. 286, 2071020726.
  • Nalls M. A., Plagnol V., Hernandez D. G. et al. (2011) Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 377, 641649.
  • Narayanan V. and Scarlata S. (2001) Membrane binding and self-association of alpha-synucleins. Biochemistry 40, 99279934.
  • Narhi L., Wood S. J., Steavenson S. et al. (1999) Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem. 274, 98439846.
  • Näsström T., Fagerqvist T., Barbu M., Karlsson M., Nikolajeff F., Kasrayan A., Ekberg M., Lannfelt L., Ingelsson M. and Bergström J. (2011a) The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of α-synuclein oligomers with distinct biochemical, morphological, and functional properties. Free Radic. Biol. Med. 50, 428437.
  • Näsström T., Gonçalves S., Sahlin C., Nordström E., Screpanti Sundquist V., Lannfelt L., Bergström J., Outeiro T. F. and Ingelsson M. (2011b) Antibodies against alpha-synuclein reduce oligomerization in living cells. PLoS ONE 6, e27230.
  • Nemani V. M., Lu W., Berge V., Nakamura K., Onoa B., Lee M. K., Chaudhry F. A., Nicoll R. A. and Edwards R. H. (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65, 6679.
  • Norris E. H., Giasson B. I., Hodara R., Xu S., Trojanowski J. Q., Ischiropoulos H. and Lee V. M. (2005) Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J. Biol. Chem. 280, 2121221219.
  • Nucifora F. C. Jr., Sasaki M., Peters M. F. et al. (2001) Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 291, 24232428.
  • Nuscher B., Kamp F., Mehnert T., Odoy S., Haass C., Kahle P. J. and Beyer K. (2004) Alpha-synuclein has a high affinity for packing defects in a bilayer membrane: a thermodynamics study. J. Biol. Chem. 279, 2196621975.
  • Nussbaum R. L. and Polymeropoulos M. H. (1997) Genetics of Parkinson's disease. Hum. Mol. Genet. 6, 16871691.
  • Olanow C. W. (1992) An introduction to the free radical hypothesis in Parkinson's disease. Ann. Neurol. 32(Suppl), S2S9.
  • Oueslati A., Fournier M. and Lashuel H. A. (2010) Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog. Brain Res. 183, 115145.
  • Outeiro T. F. and Lindquist S. (2003) Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302, 17721775.
  • Paleologou K. E., Schmid A. W., Rospigliosi C. C. et al. (2008) Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J. Biol. Chem. 283, 1689516905.
  • Paleologou K. E., Oueslati A., Shakked G. et al. (2010) Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J. Neurosci. 30, 31843198.
  • Pan-Montojo F., Schwarz M., Winkler C. et al. (2012) Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci. Rep. 2, 898.
  • Parihar M. S., Parihar A., Fujita M., Hashimoto M. and Ghafourifar P. (2008) Mitochondrial association of alpha-synuclein causes oxidative stress. Cell. Mol. Life Sci. 65, 12721284.
  • Pfeiffer S., Schmidt K. and Mayer B. (2000) Dityrosine formation outcompetes tyrosine nitration at low steady-state concentrations of peroxynitrite. Implications for tyrosine modification by nitric oxide/superoxide in vivo. J. Biol. Chem. 275, 63466352.
  • Polymeropoulos M. H., Higgins J. J., Golbe L. I. et al. (1996) Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 274, 11971199.
  • Polymeropoulos M. H., Lavedan C., Leroy E. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276, 20452047.
  • Prütz W. A., Mönig H., Butler J. and Land E. J. (1985) Reactions of nitrogen dioxide in aqueous model systems: oxidation of tyrosine units in peptides and proteins. Arch. Biochem. Biophys. 243, 125134.
  • Qin Z., Hu D., Han S., Reaney S. H., Di Monte D. A. and Fink A. L. (2007) Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J. Biol. Chem. 282, 58625870.
  • Radomski M. W., Palmer R. M. and Moncada S. (1990) Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc. Natl Acad. Sci. USA 87, 1004310047.
  • Reynolds A. D., Glanzer J. G., Kadiu I. et al. (2008) Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease. J. Neurochem. 104, 15041525.
  • Reynolds A. D., Stone D. K., Mosley R. L. and Gendelman H. E. (2009) Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4 +  T cell subsets. J. Immunol. 182, 41374149.
  • Reynolds A. D., Stone D. K., Hutter J. A., Benner E. J., Mosley R. L. and Gendelman H. E. (2010) Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J. Immunol. 184, 22612271.
  • Robotta M., Braun P., van Rooijen B., Subramaniam V., Huber M. and Drescher M. (2011) Direct evidence of coexisting horseshoe and extended helix conformations of membrane-bound alpha-synuclein. ChemPhysChem 12, 267269.
  • Robotta M., Hintze C., Schildknecht S., Zijlstra N., Jüngst C., Karreman C., Huber M., Leist M., Subramaniam V. and Drescher M. (2012) Locally resolved membrane binding affinity of the N-terminus of α-synuclein. Biochemistry 51, 39603962.
  • Rodebush W. H. and Keizer C. R. (1947) The reactions of the hydroxyl radical. J. Am. Chem. Soc. 69, 538540.
  • Santos D. and Cardoso S. M. (2012) Mitochondrial dynamics and neuronal fate in Parkinson's disease. Mitochondrion 12, 428437.
  • Schaffar G., Breuer P., Boteva R., Behrends C., Tzvetkov N., Strippel N., Sakahira H., Siegers K., Hayer-Hartl M. and Hartl F. U. (2004) Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol. Cell 15, 95105.
  • Schapira A. H., Cooper J. M., Dexter D., Clark J. B., Jenner P. and Marsden C. D. (1990) Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54, 823827.
  • Schildknecht S. and Ullrich V. (2009) Peroxynitrite as regulator of vascular prostanoid synthesis. Arch. Biochem. Biophys. 484, 183189.
  • Schildknecht S., Bachschmid M. and Ullrich V. (2005) Peroxynitrite provides the peroxide tone for PGHS-2-dependent prostacyclin synthesis in vascular smooth muscle cells. FASEB J. 19, 11691171.
  • Schildknecht S., Pape R., Müller N., Robotta M., Marquardt A., Bürkle A., Drescher M. and Leist M. (2011) Neuroprotection by minocycline caused by direct and specific scavenging of peroxynitrite. J. Biol. Chem. 286, 49915002.
  • Schildknecht S., Karreman C., Daiber A. et al. (2012a) Autocatalytic Nitration of Prostaglandin Endoperoxide Synthase-2 by Nitrite Inhibits Prostanoid Formation in Rat Alveolar Macrophages. Antioxid. Redox Signal. 17, 13931406.
  • Schildknecht S., Kirner S., Henn A., Gasparic K., Pape R., Efremova L., Maier O., Fischer R. and Leist M. (2012b) Characterization of mouse cell line IMA 2.1 as a potential model system to study astrocyte functions. ALTEX 29, 261274.
  • Scholz D., Pöltl D., Genewsky A., Weng M., Waldmann T., Schildknecht S. and Leist M. (2011) Rapid, complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line. J. Neurochem. 119, 957971.
  • Scholz D., Chernyshova Y. and Leist M. (2013) Control of Aβ release from human neurons by differentiation status and RET signaling. Neurobiol. Aging 34, 184199.
  • Scott D. A., Tabarean I., Tang Y., Cartier A., Masliah E. and Roy S. (2010) A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J. Neurosci. 30, 80838095.
  • Sevcsik E., Trexler A. J., Dunn J. M. and Rhoades E. (2011) Allostery in a disordered protein: oxidative modifications to α-synuclein act distally to regulate membrane binding. J. Am. Chem. Soc. 133, 71527158.
  • Singleton A. B., Farrer M., Johnson J. et al. (2003) Alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841.
  • Souza J. M., Daikhin E., Yudkoff M., Raman C. S. and Ischiropoulos H. (1999) Factors determining the selectivity of protein tyrosine nitration. Arch. Biochem. Biophys. 371, 169178.
  • Souza J. M., Giasson B. I., Chen Q., Lee V. M. and Ischiropoulos H. (2000) Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 275, 1834418349.
  • Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R. and Goedert M. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839840.
  • Spillantini M. G., Crowther R. A., Jakes R., Hasegawa M. and Goedert M. (1998) Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl Acad. Sci. USA 95, 64696473.
  • Stefanova N., Fellner L., Reindl M., Masliah E., Poewe W. and Wenning G. K. (2011) Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons. Am. J. Pathol. 179, 954963.
  • Steffan J. S., Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y. Z., Gohler H., Wanker E. E., Bates G. P., Housman D. E. and Thompson L. M. (2000) The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl Acad. Sci. USA 97, 67636768.
  • Stöckl M., Claessens M. M. and Subramaniam V. (2011) Kinetic measurements give new insights into lipid membrane permeabilization by α-synuclein oligomers. Mol. BioSyst. 8, 338345.
  • Stone D. K., Kiyota T., Mosley R. L. and Gendelman H. E. (2012) A model of nitric oxide induced α-synuclein misfolding in Parkinson's disease. Neurosci. Lett. 523, 167173.
  • Sung J. Y., Park S. M., Lee C. H., Um J. W., Lee H. J., Kim J., Oh Y. J., Lee S. T., Paik S. R. and Chung K. C. (2005) Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases. J. Biol. Chem. 280, 2521625224.
  • Theodore S., Cao S., McLean P. J. and Standaert D. G. (2008) Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J. Neuropathol. Exp. Neurol. 67, 11491158.
  • Tofaris G. K., Razzaq A., Ghetti B., Lilley K. S. and Spillantini M. G. (2003) Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem. 278, 4440544411.
  • Tokuda T., Qureshi M. M., Ardah M. T., Varghese S., Shehab S. A., Kasai T., Ishigami N., Tamaoka A., Nakagawa M. and El-Agnaf O. M. (2010) Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75, 17661772.
  • Ullrich V. and Schildknecht S. (2012) Sensing Hypoxia by Mitochondria: A Unifying Hypothesis Involving S-nitrosation. Antioxid. Redox Signal. doi:10.1089/ars.2012.4788.
  • Ulmer T. S., Bax A., Cole N. B. and Nussbaum R. L. (2005) Structure and dynamics of micelle-bound human alpha-synuclein. J. Biol. Chem. 280, 95959603.
  • Ulusoy A. and Di Monte D. A. (2012) α-Synuclein elevation in human neurodegenerative diseases: experimental, pathogenetic, and therapeutic implications. Mol. Neurobiol. 47, 484494.
  • Ulusoy A., Febbraro F., Jensen P. H., Kirik D. and Romero-Ramos M. (2010) Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. Eur. J. Neurosci. 32, 409422.
  • Uppu R. M., Squadrito G. L. and Pryor W. A. (1996) Acceleration of peroxynitrite oxidations by carbon dioxide. Arch. Biochem. Biophys. 327, 335343.
  • Uversky V. N. and Eliezer D. (2009) Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. Curr. Protein Pept. Sci. 10, 483499.
  • Uversky V. N., Li J. and Fink A. L. (2001a) Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem. 276, 1073710744.
  • Uversky V. N., Lee H. J., Li J., Fink A. L. and Lee S. J. (2001b) Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations. J. Biol. Chem. 276, 4349543498.
  • Uversky V. N., Yamin G., Souillac P. O., Goers J., Glaser C. B. and Fink A. L. (2002) Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. FEBS Lett. 517, 239244.
  • Uversky V. N., Yamin G., Munishkina L. A., Karymov M. A., Millett I. S., Doniach S., Lyubchenko Y. L. and Fink A. L. (2005) Effects of nitration on the structure and aggregation of alpha-synuclein. Brain Res. Mol. Brain Res. 134, 84102.
  • Vamvaca K., Volles M. J. and Lansbury P. T., Jr (2009) The first N-terminal amino acids of alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast. J. Mol. Biol. 389, 413424.
  • Vicente Miranda H. and Outeiro T. F. (2010) The sour side of neurodegenerative disorders: the effects of protein glycation. J. Pathol. 221, 1325.
  • Vieregge P., Kömpf D. and Fassl H. (1988) Environmental toxins in Parkinson's disease. Lancet 1, 362363.
  • van der Vliet A., Eiserich J. P., O'Neill C. A., Halliwell B. and Cross C. E. (1995) Tyrosine modification by reactive nitrogen species: a closer look. Arch. Biochem. Biophys. 319, 341349.
  • Vogiatzi T., Xilouri M., Vekrellis K. and Stefanis L. (2008) Wild type alpha-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J. Biol. Chem. 283, 2354223556.
  • Volles M. J., Lee S. J., Rochet J. C., Shtilerman M. D., Ding T. T., Kessler J. C. and Lansbury P. T., Jr (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 78127819.
  • Volpicelli-Daley L. A., Luk K. C., Patel T. P., Tanik S. A., Riddle D. M., Stieber A., Meaney D. F., Trojanowski J. Q. and Lee V. M. (2011) Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 5771.
  • Wassef R., Haenold R., Hansel A., Brot N., Heinemann S. H. and Hoshi T. (2007) Methionine sulfoxide reductase A and a dietary supplement S-methyl-L-cysteine prevent Parkinson's-like symptoms. J. Neurosci. 27, 1280812816.
  • Willingham S., Outeiro T. F., DeVit M. J., Lindquist S. L. and Muchowski P. J. (2003) Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science 302, 17691772.
  • Winner B., Jappelli R., Maji S. K. et al. (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl Acad. Sci. USA 108, 41944199.
  • Wislet-Gendebien S., D'Souza C., Kawarai T., St George-Hyslop P., Westaway D., Fraser P. and Tandon A. (2006) Cytosolic proteins regulate alpha-synuclein dissociation from presynaptic membranes. J. Biol. Chem. 281, 3214832155.
  • Wood S. J., Wypych J., Steavenson S., Louis J. C., Citron M. and Biere A. L. (1999) Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem. 274, 1950919512.
  • Xilouri M., Vogiatzi T., Vekrellis K., Park D. and Stefanis L. (2009) Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. PLoS ONE 4, e5515.
  • Yamin G., Uversky V. N. and Fink A. L. (2003) Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. FEBS Lett. 542, 147152.
  • Yang Q., She H., Gearing M., Colla E., Lee M., Shacka J. J. and Mao Z. (2009) Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy. Science 323, 124127.
  • Yavich L., Tanila H., Vepsäläinen S. and Jäkälä P. (2004) Role of alpha-synuclein in presynaptic dopamine recruitment. J. Neurosci. 24, 1116511170.
  • Yermolaieva O., Xu R., Schinstock C., Brot N., Weissbach H., Heinemann S. H. and Hoshi T. (2004) Methionine sulfoxide reductase A protects neuronal cells against brief hypoxia/reoxygenation. Proc. Natl Acad. Sci. USA 101, 11591164.
  • Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E. R. and Mizuno Y. (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl Acad. Sci. USA 93, 26962701.
  • Youle R. J. and van der Bliek A. M. (2012) Mitochondrial fission, fusion, and stress. Science 337, 10621065.
  • Zarranz J. J., Alegre J., Gómez-Esteban J. C. et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164173.
  • Zhang W., Wang T., Pei Z. et al. (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 19, 533542.
  • Zhou W., Gallagher A., Hong D. P., Long C., Fink A. L. and Uversky V. N. (2009) At low concentrations, 3,4-dihydroxyphenylacetic acid (DOPAC) binds non-covalently to alpha-synuclein and prevents its fibrillation. J. Mol. Biol. 388, 597610.
  • Zhou W., Long C., Reaney S. H., Di Monte D. A., Fink A. L. and Uversky V. N. (2010) Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions. Biochim. Biophys. Acta 1802, 322330.
  • Zhu M. and Fink A. L. (2003) Lipid binding inhibits alpha-synuclein fibril formation. J. Biol. Chem. 278, 1687316877.
  • Zhu M., Rajamani S., Kaylor J., Han S., Zhou F. and Fink A. L. (2004) The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. J. Biol. Chem. 279, 2684626857.